hematologic malignancy

Type: Keyphrase
Name: hematologic malignancy
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

CROs debate: Can surrogate endpoints speed oncology drugs to market?

As biopharma companies look to develop cancer therapies more quickly, some are turning to CROs with the hopes of using surrogate endpoints to expedite US FDA approval.The FDA defines a surrogate endpoint as “ a laboratory measure or a physical sign that ... [Published Outsourcing Pharma - Apr 16 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

Ocular Effects Common After Childhood Bone Marrow Transplant

PALM SPRINGS, California — Ocular complications, particularly cataract and dry eye syndrome, are common in survivors of childhood bone marrow transplantation, and the monitoring of such patients should include careful ocular screening, according to a ... [Published American Journal of Public Health - Apr 11 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 1 reports

Patent Application Titled "Method of Inhibiting Constitutively Active Phosphorylated FLT3 Kinase" Published Online

By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- According to news reporting originating from Washington, D.C. , by NewsRx journalists, a patent application by the inventor Jain, Vinay K . ( Dallas, TX ), filed on September 13, 2013 ... [Published HispanicBusiness.com - Apr 10 2014]
Entities: Kinase, Tyrosine, Mutation
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

Combined Molecular and Clinical Prognostic Index for Relapse and Survival in Cytogenetically Normal Acute Myeloid Leukemia [Hematologic Malignancy]

PurposeCytogenetically normal (CN) acute myeloid leukemia (AML) is the largest and most heterogeneous cytogenetic AML subgroup. For the practicing clinician, it is difficult to summarize the prognostic information of the growing number of clinical and ... [Published Journal of Clinical Oncology - Apr 08 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 1 reports

Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network [Hematologic Malignancy]

PurposeMantle-cell lymphoma (MCL) is a distinct B-cell lymphoma associated with poor outcome. In 2008, the MCL International Prognostic Index (MIPI) was developed as the first prognostic stratification tool specifically directed to patients with MCL. ... [Published Journal of Clinical Oncology - Apr 01 2014]
First reported Mar 27 2014 - Updated Mar 27 2014 - 1 reports

Patients with hematologic malignancies received more aggressive end-of-life care

Patients with blood cancers received substantially more aggressive care in their final 30 days of life than those with solid tumors, according to results of a retrospective cohort study.Results showed individuals with hematologic malignancies were more ... [Published Orthopedics Today - Mar 27 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 1 reports

Agios doses first patient in Phase I of mutated metabolic gene study

Agios Pharmaceuticals, Inc., a provider of drugs to treat cancer and inborn errors of metabolism, has announced that it has dosed first patient in a Phase I study of AG-120 in patients with hematologic malignancies with an isocitrate dehydrogenase-1, ... [Published Individual.com - Mar 25 2014]
Entities: Mutation, Phase I, Cancer
First reported Mar 20 2014 - Updated Mar 20 2014 - 1 reports

Contributions of the Host Microenvironment to Cancer-Induced Bone Disease

The bone marrow provides a specialized and highly supportive microenvironment for tumor growth and development of the associated bone disease. It is a preferred site for breast and prostate cancer bone metastasis and the hematologic malignancy, multiple ... [Published Bionity.com - Mar 20 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 2 reports

Agios Pharmaceuticals enrolls first patient in Phase 1 AG-120 study

Agios Pharmaceuticals (AGIO) announced that the first patient has been dosed in a Phase 1 study of AG-120 in patients with advanced hematologic malignancies with an isocitrate dehydrogenase-1 mutation. AG-120 is an orally available, selective, potent ... [Published Yahoo! Finance - Mar 19 2014]
First reported Mar 18 2014 - Updated Mar 18 2014 - 1 reports

Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study [Hematologic Malignancy]

PurposeMost patients with chronic lymphocytic leukemia (CLL) are elderly and/or have comorbidities that may make them ineligible for fludarabine-based treatment. For this population, chlorambucil monotherapy is an appropriate therapeutic option; however, ... [Published Journal of Clinical Oncology - Mar 18 2014]
First reported Mar 14 2014 - Updated Mar 14 2014 - 1 reports

This Week in Blood: March 13, 2014

2014-03-13(WASHINGTON)– Welcome to “This Week in Blood,” a weekly snapshot of the hotteststudies from each week’s issue of Blood ,the official journal of the AmericanSociety of Hematology (ASH), hand-picked by BloodEditor-in-Chief Bob Löwenberg, MD, ... [Published American Society of Hematology - Mar 14 2014]
First reported Mar 14 2014 - Updated Mar 14 2014 - 1 reports

Assistant Vice President for Medical Advancement

Stony Brook MedicineStony Brook University Stony Brook University has established itself as one of America’s most dynamic public universities, a center of academic excellence and an essential part of the region’s economy. Now, transformed by a historic ... [Published Charity Channel - Mar 14 2014]

Quotes

"With medical advances, children requiring bone marrow transplant for various hematologic malignancies, solid tumors, and nonmalignant diseases have increasing survival rates" said first author Julie Calderwood, MD, senior ophthalmology resident at the University of Tennessee Health Science Center in Memphis
...background information on this patent application, NewsRx editors also obtained the inventor's summary information for this patent application: "The present invention includes a method of inhibiting or reducing deregulated FLT3 tyrosine kinase activity or expression in a subject with a proliferative disease which comprises administering to the subject having or suspected to have the proliferative disease, a therapeutically or prophylactically effective amount of the compound of Formula I:"

More Content

All (24) | News (24) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
CROs debate: Can surrogate endpoints speed onco... [Published Outsourcing Pharma - Apr 16 2014]
Variants of humanized immunomodulatory monoclon... [Published PharmCast - Apr 15 2014]
Ocular Effects Common After Childhood Bone Marr... [Published American Journal of Public Health - Apr 11 2014]
Patent Application Titled "Method of Inhibiting... [Published HispanicBusiness.com - Apr 10 2014]
Combined Molecular and Clinical Prognostic Inde... [Published Journal of Clinical Oncology - Apr 08 2014]
A Physician-Businessman's Views Of Gilead, With... [Published Seeking Alpha - Apr 07 2014]
FDA Approves Merck's NOXAFIL posaconazole Injec... [Published Pharmacy Choice - Apr 02 2014]
Confirmation of the Mantle-Cell Lymphoma Intern... [Published Journal of Clinical Oncology - Apr 01 2014]
Patients with hematologic malignancies received... [Published Orthopedics Today - Mar 27 2014]
FDA Approves Merck's NOXAFIL® posaconazole Inje... [Published 4 Traders - Mar 26 2014]
Agios doses first patient in Phase I of mutated... [Published Individual.com - Mar 25 2014]
Agios enrolls first patient in phase I study of... [Published Center Watch - Mar 21 2014]
Contributions of the Host Microenvironment to C... [Published Bionity.com - Mar 20 2014]
Agios Pharmaceuticals enrolls first patient in ... [Published Yahoo! Finance - Mar 19 2014]
Agios Pharma: First Patient Enrolled In Phase 1... [Published RTTNews.com - Mar 19 2014]
FDA Approves Merck’s NOXAFIL (posaconazole) Inj... [Published FirstWord Pharma - Mar 19 2014]
Rituximab Plus Chlorambucil As First-Line Treat... [Published Journal of Clinical Oncology - Mar 18 2014]
Fate Therapeutics' CEO Discusses Q4 2013 Result... [Published Seeking Alpha - Mar 18 2014]
FDA Approves Merck's NOXAFIL® (posaconazole) In... [Published CNBC - Mar 14 2014]
This Week in Blood: March 13, 2014 [Published American Society of Hematology - Mar 14 2014]
Assistant Vice President for Medical Advancement [Published Charity Channel - Mar 14 2014]
CHMP Issues Positive Opinion for Tablet Formula... [Published 4 Traders - Mar 12 2014]
ImmunoGen Inc. Announces Favorable Initial Safe... [Published BioPortfolio - Dec 09 2013]
Therapeutic use of anti-CS1 antibodies [Published PharmCast - Jun 25 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.